PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation

In conclusion, pembrolizumab was successfully administered as post-ASCT consolidation in patients with RR cHL, and resulted in a promising PFS in a high-risk patient cohort, supporting the testing of this strategy in a randomized trial. This trial was registered at www.clinicaltrials.gov as #NCT02362997.

Source: Blood - July 3, 2019 Category: Hematology Authors: Armand, P., Chen, Y.-B., Redd, R. A., Joyce, R. M., Bsat, J., Jeter, E., Merryman, R. W., Coleman, K. C., Dahi, P. B., Nieto, Y., LaCasce, A. S., Fisher, D. C., Ng, S. Y., Odejide, O. O., Freedman, A. S., Kim, A. I., Crombie, J. L., Jacobson, C. A., Jacob Tags: Immunobiology and Immunotherapy, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research